**HIP RESURFACING AND REPLACEMENT SURGERY (ARTHROPLASTY)**

**Policy Number:** 2019T0503Q  
**Effective Date:** April 1, 2019

**Table of Contents**

- **COVERAGE RATIONALE** ........................................ 1  
- **APPLICABLE CODES** ........................................... 1  
- **U.S. FOOD AND DRUG ADMINISTRATION** .................... 2  
- **CENTERS FOR MEDICARE AND MEDICAID SERVICES** ....... 2  
- **POLICY HISTORY/REVISION INFORMATION** ................... 2  
- **INSTRUCTIONS FOR USE** ...................................... 2

**COVERAGE RATIONALE**

**Hip Replacement Surgery (Arthroplasty)**

Hip replacement surgery (arthroplasty) is proven and medically necessary in certain circumstances. For medical necessity clinical coverage criteria, see the following MCG™ Care Guidelines, 23rd edition, 2019:

- Hip Arthroplasty, S-560 (ISC)
- Hip: Displaced Fracture of Femoral Neck, Hemiarthroplasty, S-600 (ISC)

**Hip Resurfacing Arthroplasty**

Hip resurfacing is proven and medically necessary in certain circumstances. For medical necessity clinical coverage criteria, see MCG™ Care Guidelines, 23rd edition, 2019, Hip Resurfacing, S-565 (ISC).

**APPLICABLE CODES**

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines may apply.

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>27120</td>
<td>Acetabuloplasty (e.g., Whitman, Colonna, Haygroves, or cup type)</td>
</tr>
<tr>
<td>27122</td>
<td>Acetabuloplasty; resection, femoral head (e.g., Girdlestone procedure)</td>
</tr>
<tr>
<td>27125</td>
<td>Hemiarthroplasty, hip, partial (e.g., femoral stem prosthesis, bipolar arthroplasty)</td>
</tr>
<tr>
<td>27130</td>
<td>Arthroplasty, acetabular and proximal femoral prosthetic replacement (total hip arthroplasty), with or without autograft or allograft</td>
</tr>
<tr>
<td>27132</td>
<td>Conversion of previous hip surgery to total hip arthroplasty, with or without autograft or allograft</td>
</tr>
<tr>
<td>27134</td>
<td>Revision of total hip arthroplasty; both components, with or without autograft or allograft</td>
</tr>
<tr>
<td>27137</td>
<td>Revision of total hip arthroplasty; acetabular component only, with or without autograft or allograft</td>
</tr>
<tr>
<td>27138</td>
<td>Revision of total hip arthroplasty; femoral component only, with or without allograft</td>
</tr>
</tbody>
</table>

*CPT® is a registered trademark of the American Medical Association*
HCPCS Code | Description
--- | ---
S2118 | Metal-on-metal total hip resurfacing, including acetabular and femoral components

**U.S. FOOD AND DRUG ADMINISTRATION (FDA)**

Hip replacement surgery is a procedure and therefore is not regulated by the FDA. However, devices and instruments used during the surgery require FDA approval. Several devices have FDA approval. Additional information (product code MEH, JDI, JDG, LWJ, LPH, LZO, KWY, KWA) is available at: [https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmncfm](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmncfm). (Accessed January 2, 2019)

Total hip resurfacing systems are approved by the FDA Premarket Approval (PMA) process. Additional information (product code NXT) is available at: [https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm). (Accessed January 2, 2019)

In January 2013, the FDA issued a safety communication regarding the ongoing concern related to adverse events associated with increased blood levels of cobalt and chromium following implant of MoM systems. The communication acknowledged reports in the medical literature of the potential for systemic effects of elevated metal ion levels resulting from device wear in MoM hip. At this time, however, the current body of evidence is insufficient to identify any specific metal ion levels that would cause adverse effects (FDA, 2013).

**CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS)**

Medicare does not have a National Coverage Determination (NCD) for hip replacement surgery or hip resurfacing arthroplasty. Local Coverage Determinations (LCDs) exist; see the LCDs for **Lower Extremity Major Joint Replacement (Hip and Knee)**, **Major Joint Replacement (Hip and Knee)**, **Total Hip Arthroplasty** and **Total Joint Arthroplasty**. (Accessed January 11, 2019)

**POLICY HISTORY/REVISION INFORMATION**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
</table>
| 04/01/2019 | • Revised coverage rationale:  
|            |   o Replaced references to "MCG™ Care Guidelines, 22nd edition, 2018” with "MCG™ Care Guidelines, 23rd edition, 2019”; refer to 23rd edition for complete details on applicable updates to the MCG™ Care Guidelines  
|            |   • Updated list of applicable CPT codes; removed 27299  
|            |   • Updated supporting information to reflect the most current FDA and CMS information  
|            |   • Archived previous policy version 2018T0503P |

**INSTRUCTIONS FOR USE**

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence ([Medicare IOM Pub. No. 100-16, Ch. 4, §90.5](https://www.cms.gov/Medicare/Research-Statistics-Data-and-Systems/Research finds/Downloads/Medicare-IOM-Pub-No-100-16-Ch-4.pdf)).

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.